

Employer Oncology Management & Benefit Design

SUMMARY OF KEY FINDINGS | SEPTEMBER 2017

Key Research Findings

This is a summary of our research on Employer Oncology Management & Benefit Design focused on new and innovative solutions.

As a large employer or employer health coalition looking to improve value in cancer care, we hope you find this report insightful. Don't hesitate to contact us with your questions and comments.

Thank You, The Benfield Team

Sarah Daley Research Director (314) 656-2384 Sarah_Daley@ajg.com Jack Nightingale Area Vice President (703) 847-0272 Jack_Nightingale@ajg.com

Contents

- » Cancer as a Workforce Issue
- » Oncology Benefit Design
- » Value-Driven Approaches to Oncology Management
- » Vendor Support For Employer Oncology Management

Methodology & Panel Overview

Employer Interviews

28 Total Interviews

3.1 Million Covered Lives Represented

Respondent Organizational Position:

VP of Benefits | **32%** Benefits Director | **25%** Benefits Manager | **25%** Medical Director | **18%**

Average Employer Size: 100,000 U.S. Employees

7 Additional Healthcare Stakeholder Interviews:

2 Provider Organizations, Health Plan, PBM, Benefits Advisor, Rx Purchasing Coalition, National Guideline Organization

Employer Surveys

80 Total Interviews

4.6 Million Covered Lives Represented

Respondent Organizational Position:



Benefits Director | 36% Benefits Manager | 24% VP of Benefits | 23% Medical Director | 10% Benefits Analyst | 7%

Average Employer Size: 57,000 U.S. Employees

CANCER AS A WORKFORCE ISSUE

Although cancer has been an employer concern for a number of years, growth in importance is expected as treatment options and costs increase

Importance of Managing Cancer: 2 Years Ago vs. Now


Consistently of high concern

• No dramatic change in importance of cancer

Employers observe strong improvements in:

- Detection
- Ability to guide patients to high quality, evidence-based care
- Treatment (but also far more expensive)
- Outcomes


Trends in Importance of Managing Cancer to Employers



2013 n=106; Now (2016) n=27); In 2 Years (by 2018) n=26

"Cancer is not one disease, it's many different diseases and as treatment becomes more advanced and more personalized, we expect it will get more complex and expensive." –Employer

Currently just 22% of employers indicate that they are taking significant steps to manage cancer, but 64% expect to do so in two years




Employer Focus on Cancer

n=80 Employers


Employers are overwhelmingly focused on breast cancer

Top Cancer Types of Employer Focus



Increasing prices for cancer drugs and the shift from traditional to specialty cancer drugs are viewed by employers as having the greatest impact on cancer costs


> Top 5 Factors Driving Increasing Costs of Cancer Care (percentage indicating high impact)



9


On one hand, most employers rely heavily on their PBMs to implement tactics to control Rx costs; on the other hand, most employers are hesitant about restricting access to treatments

Employer Perspectives on Managing Cancer



Most employers believe early detection is key to managing cancer costs; over 80% point to quality improvements via evidence-based treatment and use of top-tier providers to achieve this goal

Top 5 Opportunities for Controlling or Reducing Costs of Cancer Care




(percentage indicating high importance)

ONCOLOGY BENEFIT DESIGN

Employer expectations show a notable shift toward more restrictive cancer policies by 2019

Employer Treatment of Cancer-Specific Medical and Pharmacy Benefits




» Examples of benefit design unique to cancer:

- Variable support services & Centers of Excellence designation
- Amplified PAs & dosing limits on oncology Rx
- Clinical trial coverage for rare cancers
- Coverage of genomic testing for certain cancers

Employers currently deploy a variety of benefit design and program features to manage cancer, especially screenings, case management and employee education


Cancer Management Benefit Design & Programs

(offered directly or via health plan)



There is room for improvement as no more than half of employers view any of their cancer management solutions to be highly successful

Success of Cancer Management Benefit Design & Programs (among employers offering)



Medications through Medical Benefit vs. Pharmacy Benefit

- » 75%+ can/do distinguish medical and pharmacy benefit costs
 - Primarily via data warehouse or health plan
 - "Not easy to do"
- » Few have efforts underway to move all medical Rx to pharmacy benefit
 - Cost savings not there
 - Administrative complexity
 - Fear treatment disruption, interference with provider-patient care decisions
 - Would require re-negotiating provider contracts; oncologists very reluctant to lose profit margin

"There is the challenge of keeping providers happy. If you move chemo to specialty pharma benefits, you have to deal with the fact that 50% of their compensation is from chemo." –Health Plan


Perspectives on site-of-care issues & dynamics: Half of interviewed employers have taken action or would like to do so



VALUE-DRIVEN APPROACHES TO ONCOLOGY MANAGEMENT

Employers look to value-based approaches to influence which healthcare providers their employees select or the treatment plans and therapies the providers recommend

Value-Based Approaches to Cancer Management




Employers have limited familiarity with value frameworks

A value framework is a tool to assess the relative value of cancer therapies. Examples include ICER (Institute for Clinical and Economic Review), Sloan Kettering Cancer Center's Drug Abacus and the American Society of Clinical Oncologists framework.

So far, the **value frameworks are in the early stage of adoption**. Provider organizations may use them in developing their own clinical pathways. Some health plans that want to promote provider compliance with these value frameworks are offering them PMPM payments based on compliance. Employers have limited awareness, and those that are familiar question the methodology and transparency of methodology for the frameworks.

Familiarity with Value Frameworks Focused on Treatment Quality and Cost



Barriers to use of value frameworks:


- » Provider buy-in
- » Difficulty for providers to align with multiple frameworks
- » Clarity of methodology—must be unbiased
- » Limited employer bandwidth to implement benefit designs that support framework

© 2017 Benfield, a division of Gallagher Benefit Services, Inc. Employer Oncology Management & Benefit Design.

VENDOR SUPPORT FOR EMPLOYER ONCOLOGY MANAGEMENT

Employers most often cite their health plan as having the strongest influence on cancer management and benefit design

Most Influential Stakeholder in Employer's Cancer Management and Benefit Design Decisions



*Other includes: Health systems management n=24 Employers


"We would weigh the medical carriers and PBM's clinical opinions the highest, but with some reservation about trying to tack on additional products/services they offer for additional fees." –Employer

"Our advisors come in once a quarter and tell us what is most cutting edge in the field, including oncology." –Employer

"Providers occasionally come on site to do lunch and learns and seminars for staff." –Employer

Employers rely on their health plan and SPP/PBM for oncology insights, but also look to NBGH and other non-vendor sources

Extent that Vendor Provides Information and Insights About Cancer Care



Non-Vendor Resources

- National Business Group on Health (NBGH)
- Regional Health Coalitions
- Employer organizations/ associations (e.g., IBI, EBRI)
- Conferences
- Health Transformation Alliance (HTA)
- Medical journals
- Peers



Benfield | Arthur J. Gallagher & Co., St. Louis, MO 63119 © Benfield, a division of Gallagher Benefit Services, Inc. All rights reserved.

This Report is licensed only to the original party licensed by Benfield, a division of Gallagher Benefit Services, Inc. (respectively the "Licensee" and "Benfield-Gallagher") and is subject to a binding license agreement between Licensee and Benfield-Gallagher. Benfield-Gallagher continues to retain title to and ownership of this Report. All copies and portions of this Report, in any form, belong to Benfield-Gallagher, which retains all rights not expressly granted. Licensee is entitled to use this Report solely for its own internal business purposes and is prohibited from modifying, translating, or otherwise creating derivative works based on this Report. Licensee is further prohibited from licensing, selling, leasing, distributing, lending or otherwise transferring this Report to any third party. Licensee may not make any copies of Benfield-Gallagher's protective notices, including this and all copyright notices. Nothing in this Report and/or license agreement applicable thereto constitute a waiver of Benfield-Gallagher's rights under United States Copyright law or any other law.

This information has been obtained from sources which Benfield-Gallagher believes to be reliable but we do not guarantee the accuracy or completeness of this information.

Benfield's area of focus is the marketplace influence of jumbo employers (5000+ employees), leading employer health coalitions, and employer benefits consultants and brokers.

JACK NIGHTINGALE

Area Vice President Jack_Nightingale@ajg.com P: 703.847.0272 SARAH DALEY Research Director Sarah_Daley@ajg.com P: 314.656.2384